Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
25 pending office actions • 15 art units • 25 examiners • 0 of 25 (0%) have an AI response strategy ready • 22 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (16%) |
| §102 only | 2 (8%) |
| §112 only | 1 (4%) |
| Double-patenting only | 3 (12%) |
| Double-patenting + other | 8 (32%) |
| Multi-statute (no §101) | 7 (28%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KRINOS, EMILY LYNN | 1 | — | — |
| PALENIK, JEFFREY T | 1 | 53.6% | +27.2% |
| SOROUSH, LAYLA | 1 | 40.5% | +43.4% |
| SPENCE, JENNIFER SUZANNE | 1 | 66.4% | +47.5% |
| DAVIS, BRIAN J | 1 | 84.8% | -4.0% |
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
| REDWOOD, CHRISTOPHER EVAN | 1 | 0.0% | +0.0% |
| RAHMANI, NILOOFAR | 1 | 77.6% | -3.1% |
| GRABER, JAMES J | 1 | 46.4% | +57.5% |
| DICKINSON, PAUL W | 1 | 63.1% | +9.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18794848 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | DAVIS, BRIAN J | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17669874 | PANCREATIC DIFFERENTIATION | BATES, KEENAN ALEXANDER | 37d overdue |
| 18018787 | IN VITRO DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | ROGERS, ERIC JASON | 28d |
| 19100776 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | KRINOS, EMILY LYNN | — |
| 18835221 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | REDWOOD, CHRISTOPHER EVAN | — |
| 18707756 | STEM CELL DIFFERENTIATION AND CHEMICAL COMPOUNDS | GRABER, JAMES J | — |
| 18456269 | Compositions and Methods for Treatment of Myotonic Dystrophy Type 1 with CRISPR/SACAS9 | VIJAYARAGHAVAN, JAGAMYA NMN | — |
| 18270314 | ENHANCED DIFFERENTIATION OF BETA CELLS | MONTANARI, DAVID A | — |
| 18030520 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | MARTIN, KEVIN STEPHEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18999125 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF | PALENIK, JEFFREY T | — |
| 18972540 | DOSING REGIMENS FOR TREATING PAIN | SOROUSH, LAYLA | — |
| 18904543 | DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | SPENCE, JENNIFER SUZANNE | — |
| 18791880 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | O DELL, DAVID K | — |
| 18707756 | STEM CELL DIFFERENTIATION AND CHEMICAL COMPOUNDS | GRABER, JAMES J | — |
| Art Unit | Apps |
|---|---|
| 1624 | 2 |
| 1628 | 2 |
| 1626 | 2 |
| 1691 | 2 |
| 1615 | 1 |
| 1622 | 1 |
| 1614 | 1 |
| 1618 | 1 |
| 1627 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19100776 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | KRINOS, EMILY LYNN | 1615 | §102§103§112 | Non-Final OA | — | Pending | Feb 03, 2025 |
| 18999125 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF | PALENIK, JEFFREY T | — | DP | Non-Final OA | — | Pending | Dec 23, 2024 |
| 18972540 | DOSING REGIMENS FOR TREATING PAIN | SOROUSH, LAYLA | 1622 | §103 | Non-Final OA | — | Pending | Dec 06, 2024 |
| 18904543 | DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | SPENCE, JENNIFER SUZANNE | — | §102§103DP | Non-Final OA | — | Pending | Oct 02, 2024 |
| 18794848 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | DAVIS, BRIAN J | 1614 | §112 | Non-Final OA | — | Pending | Aug 05, 2024 |
| 18791880 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | O DELL, DAVID K | — | §103DP | Non-Final OA | — | Pending | Aug 01, 2024 |
| 18835221 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | REDWOOD, CHRISTOPHER EVAN | — | §103§112DP | Non-Final OA | — | Pending | Aug 01, 2024 |
| 18775146 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | RAHMANI, NILOOFAR | — | §112DP | Non-Final OA | — | Pending | Jul 17, 2024 |
| 18707756 | STEM CELL DIFFERENTIATION AND CHEMICAL COMPOUNDS | GRABER, JAMES J | — | §102§103 | Non-Final OA | — | Pending | May 06, 2024 |
| 18647137 | STEM CELL DERIVED PANCREATIC ISLET DIFFERENTIATION | DICKINSON, PAUL W | 1618 | §103 | Final Rejection | 26d overdue | Pending | Apr 26, 2024 |
| 18566279 | SUBSTITUTED TETRAHYDROFURAN ANALOGS AS MODULATORS OF SODIUM CHANNELS | BORALSKY, LUKE ALAN | 1624 | §112DP | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18566176 | SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE | RAO, PADMAJA S | 1627 | §102Other | Final Rejection | 52d overdue | Pending | Dec 01, 2023 |
| 18566297 | SUBSTITUTED TETRAHYDROFURAN-2-CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | CLARK, AMY LYNN | 1628 | §112DP | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18456269 | Compositions and Methods for Treatment of Myotonic Dystrophy Type 1 with CRISPR/SACAS9 | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §103§112Other | Non-Final OA | — | Pending | Aug 25, 2023 |
| 18270314 | ENHANCED DIFFERENTIATION OF BETA CELLS | MONTANARI, DAVID A | 1632 | §102§103 | Non-Final OA | — | Pending | Jun 29, 2023 |
| 18030519 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | KUCKLA, ANNA GRACE | 1626 | §102 | Non-Final OA | — | Pending | Apr 06, 2023 |
| 18030520 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | MARTIN, KEVIN STEPHEN | 1624 | §102§112 | Non-Final OA | — | Pending | Apr 06, 2023 |
| 18030518 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VISHNYAKOVA, ELENA VLADIMIROVNA | 1691 | §103 | Final Rejection | 7d | Pending | Apr 06, 2023 |
| 18018787 | IN VITRO DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | ROGERS, ERIC JASON | 1638 | §102§103§112 | Final Rejection | 28d | Pending | Jan 30, 2023 |
| 17820773 | METHOD FOR TREATING CANCER USING A COMBINATION OF DNA DAMAGING AGENTS AND ATR INHIBITORS | HOWELL, THEODORE R | 1628 | §103DP | Non-Final OA | 25d overdue | Pending | Aug 18, 2022 |
| 17669874 | PANCREATIC DIFFERENTIATION | BATES, KEENAN ALEXANDER | 1631 | §102§103 | Non-Final OA | 37d overdue | Pending | Feb 11, 2022 |
| 17469665 | Compositions and Methods for Treatment of Duchenne Muscular Dystrophy | TATGE, LEXUS MARC | 1600 | §103DP | Non-Final OA | — | Pending | Sep 08, 2021 |
| 17345256 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | CHICKS, ASHLI ARIANA | 1626 | §103Other | Non-Final OA | 18d overdue | Pending | Jun 11, 2021 |
| 17293632 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | LEE, HOI YAN NMN | 1693 | DP | Final Rejection | — | Pending | May 13, 2021 |
| 17122543 | GCN2 INHIBITORS AND USES THEREOF | LEE, ANDREW P | 1691 | DP | Final Rejection | — | Pending | Dec 15, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial